Mayne Pharma Group (OTCMKTS:MAYNF – Get Free Report) will likely be releasing its resultson Thursday, August 27th. Analysts expect Mayne Pharma Group to post earnings of ($0.2359) per share and revenue of $115.3910 million for the quarter.
Mayne Pharma Group Stock Performance
Shares of OTCMKTS:MAYNF opened at $2.30 on Tuesday. The business has a fifty day moving average price of $1.97 and a 200-day moving average price of $1.81. Mayne Pharma Group has a 1-year low of $1.40 and a 1-year high of $4.00.
Mayne Pharma Group Company Profile
Mayne Pharma Group (OTCMKTS:MAYNF) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of prescription products. The company’s portfolio spans oral, transdermal and topical dosage forms, with a particular emphasis on women’s health, dermatology, pain management and other niche therapeutic areas. Through both branded and generic offerings, Mayne Pharma seeks to address unmet patient needs and provide cost-effective alternatives to established treatments.
In its development operations, Mayne Pharma leverages a combination of in-house research and external partnerships to advance product candidates through regulatory review.
Recommended Stories
- Five stocks we like better than Mayne Pharma Group
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Mayne Pharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mayne Pharma Group and related companies with MarketBeat.com's FREE daily email newsletter.
